Beeline Medicines
Biotech · Healthcare
Beeline Medicines adds $126.3M to massive Series A
June 30, 2026$126M · Series A extension
Beeline Medicines closed a $126.3 million Series A extension, lifting the round to $426.3 million to advance lupus and autoimmune programs.
Lead Investors
Bain CapitalCanada Pension Plan Investment BoardBristol Myers Squibb
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.